GPRC5D
62 programs · 61 companies
Programs
62
Companies
61
Active Trials
50
Targeting GPRC5D
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Pexatenlimab | Novartis | Phase 1/2 | Hemophilia AHCC | |
| Ribotuximab | Merck & Co | Phase 2 | CMLRB | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | ALLALS | |
| NVO-7877 | Novo Nordisk | Preclinical | Ovarian CaSCLC | |
| AMG-9654 | Amgen | Phase 2 | RBHuntington's | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | PBC | |
| Ribozanubrutinib | Genmab | Approved | LNGBM | |
| ASN-7408 | Ascendis Pharma | NDA/BLA | PSP | |
| RVM-3746 | Revolution Medicines | Phase 1/2 | IPFLN | |
| Rimabrutinib | Madrigal Pharma | Phase 1/2 | PNHEpilepsy | |
| Cevizasiran | Acadia Pharma | Phase 1/2 | CF | |
| MRU-1869 | Merus | Approved | RB | |
| Rilunesiran | Apogee Ther | Phase 1/2 | GA | |
| Liravorutinib | Biomea Fusion | Phase 1/2 | HNSCCSchizophrenia | |
| PAS-2221 | Passage Bio | Preclinical | ASFTD | |
| ARC-1235 | Arcturus | Phase 3 | GISTCRC | |
| Teraosocimab | Grifols | Phase 3 | Fabry | |
| CSL-5840 | CSL Limited | Phase 3 | Celiac | |
| Bemabrutinib | Zai Lab | Phase 1 | NBCF | |
| Voxarapivir | Zai Lab | Phase 2 | Hemophilia ALGS | |
| 992-9448 | Akeso | Preclinical | MelanomaMM | |
| Gozecagene | BioArctic | Phase 1 | NMOSDACC | |
| GUS-IIT-973 | Gustave Roussy | Phase 2 | RSV | |
| EOR-IIT-902 | EORTC | NDA/BLA | Bladder Ca | |
| MAS-IIT-787 | Mass General Brigham | Phase 1 | Heart Failure | |
| Tixazanubrutinib | Imvax | Approved | PTSD | |
| Mirirelsin | ARCH Venture | Phase 1/2 | ET | |
| Talabrutinib | Athenex | Phase 1/2 | HNSCCFL | |
| PRT-4395 | Paratek Pharma | Phase 2 | Heart FailureGBM | |
| Polarasimod | CStone Pharma | Phase 3 | DMDIPF | |
| CLE-2655 | Clementia (Ipsen) | Phase 2 | Pancreatic CaBladder Ca | |
| GLO-9656 | Gloria Biosciences | NDA/BLA | RA | |
| 086-7390 | Medytox | Phase 2/3 | Cervical Ca | |
| Lisolemzoparlimab | Affinia | Preclinical | HS | |
| AJA-7840 | Ajax Ther | NDA/BLA | RA | |
| Rilufutibatinib | Dyno Ther | Phase 3 | CRCNarcolepsy | |
| Miriderotide | Pieris Pharma | Phase 1/2 | FabryProstate Ca | |
| INT-3699 | Intercept (Alfasigma) | Preclinical | AngelmanHeart Failure | |
| Fixatuximab | StrideBio | Phase 3 | Psoriasis | |
| SLN-495 | Silence Ther | Phase 1 | RCC | |
| Darafutibatinib | Kyowa Kirin | NDA/BLA | PompeParkinson's | |
| Zenovorutinib | Noile-Immune | Phase 2 | ObesityMigraine | |
| Voxafutibatinib | GC Pharma | Phase 1/2 | PSPCRC | |
| 4D-8297 | 4D Pharma | Phase 1/2 | Heart Failure | |
| TCB-6877 | TC BioPharm | Phase 1/2 | FSGSNMOSD | |
| Lisosotorasib | Myriad Genetics | Phase 3 | MCCCSU | |
| POL-2929 | Polyphor | Phase 2/3 | EoEEndometrial Ca | |
| Miriratamab | Bayer AG | Phase 2/3 | Gastric CaHNSCC | |
| SLN-6859 | Silence Therapeutics | Phase 2 | CTCLFTD | |
| Adagraratamab | Richmond Lab | Phase 1 | PAH | |
| APN-6857 | Aspen Pharmacare | Phase 2 | MCCUC | |
| AIP-7637 | Adcock Ingram | NDA/BLA | IPFFabry | |
| Polalemzoparlimab | Nobel Ilac | Approved | Hemophilia AOCD | |
| CHA-IIT-211 | Charité Berlin | Phase 1 | Bladder Ca | |
| INS-IIT-594 | Institut Curie | Approved | Celiac | |
| AII-IIT-903 | AIIMS New Delhi | NDA/BLA | EoE | |
| Rimamavacamten | Scientus Pharma | Preclinical | RettADPKD | |
| Zanusotorasib | West Pharma | Phase 2/3 | IPFHCC | |
| Tezevorutinib | Zentiva | Preclinical | FSGS | |
| VIR-467 | Virbac | Phase 3 | DMDPSP | |
| DYN-9663 | Dyne Therapeutics | Approved | SchizophreniaFabry | |
| Sovalemzoparlimab | Seer | Phase 3 | MSMigraine |